ORTX - Gene Therapy Stocks - A Buying Opportunity
- Some gene therapy stocks including ORTX, QURE and RGNX are trading considerably lower than in January of 2020.
- ORTX, QURE and RGNX have all had issues unique to their businesses which may explain the depressed share prices.
- Recently, the FDA has taken a tougher stance on gene therapy in diseases where patients have viable treatment options which may have caused further declines in share price.
- ORTX shares appears materially undervalued, QURE offers a high degree of risk and a very substantial upside and RGNX can potentially recover if they produce compelling clinical data.
For further details see:
Gene Therapy Stocks - A Buying Opportunity